共 214 条
[11]
Barreca M(2017)Breast cancer Lancet 389 1134-117
[12]
Lang N(2011)Improved curve fits to summary survival data: application to economic evaluation of health technologies BMC Med Res Methodol 11 139-250
[13]
Tarantelli C(2023)Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial Lancet 401 105-19
[14]
Spriano F(2013)Consolidated Health Economic Evaluation Reporting Standards (CHEERS)–explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force Value Health 16 231-205
[15]
Barraja P(2022)Chinese society of clinical oncology (CSCO) Breast Cancer Guidelines 2022 Translatl Breast Cancer Res 3 13-1769
[16]
Bertoni F(2020)Antibody-Drug Conjugates: A Comprehensive Review Mol Cancer Res 18 3-1161
[17]
Bertram MY(2023)Tucatinib vs Placebo, Both in Combination With Trastuzumab and Capecitabine, for Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer in Patients With Brain Metastases: Updated Exploratory Analysis of the HER2CLIMB Randomized Clinical Trial JAMA Oncol 9 197-621
[18]
Lauer JA(2021)Breast cancer Lancet 397 1750-510
[19]
De Joncheere K(2015)The Evolving Landscape of HER2 Targeting in Breast Cancer JAMA Oncol 1 1154-380
[20]
Edejer T(2020)Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer N Engl J Med 382 610-1103